Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease
| Autor: | Laura E. Derby, David A. Drachman, Gwen L. Zornberg, Marian Wald Myers, Sudha Seshadri, Hershel Jick |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Population Cohort Studies Arts and Humanities (miscellaneous) Alzheimer Disease Risk Factors Internal medicine medicine Humans Risk factor education Aged education.field_of_study business.industry Estrogen Replacement Therapy Case-control study Estrogens Odds ratio medicine.disease Surgery Menopause Postmenopause Estrogen Case-Control Studies Cohort Female Neurology (clinical) Progestins business Cohort study Follow-Up Studies |
| Zdroj: | Archives of neurology. 58(3) |
| ISSN: | 0003-9942 |
| Popis: | Background Previous studies have examined the relation between postmenopausal estrogen replacement therapy (ERT) and the risk of Alzheimer disease (AD). The findings have been inconsistent, since some studies have been interpreted as showing a protective effect while others have reported no effect. Objective To determine whether exposure to ERT is associated with a reduced risk of AD. Design Population-based nested case-control study. Setting The United Kingdom–based General Practice Research Database. Patients The base cohort consisted of women who were recipients of ERT (n = 112 481) and a similar cohort of women who did not use estrogens (n = 108 925). The 2 cohorts were restricted to women born on or before January 1, 1950. From the 2 cohorts, we identified and verified 59 newly diagnosed cases of AD and 221 matched control subjects. Main Outcome Measure Prior and current use of ERT in cases compared with controls. Results Among the 59 newly diagnosed cases of AD, 15 (25%) were current estrogen users, while among the controls, 53 (24%) were current users. The adjusted odds ratio comparing all current estrogen recipients with nonrecipients was 1.18 (95% confidence interval, 0.59-2.37). In estrogen users who took the drug for 5 years or longer compared with nonusers, the odds ratio was 1.05 (95% confidence interval, 0.32-3.44). Odds ratios were similar for estrogen recipients who received estrogens alone and recipients who received combined estrogen-progestin treatment. Conclusion The use of ERT in women after the onset of menopause was not associated with a reduced risk of developing AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|